Publications
Berd D, Sato T, Maguire HC Jr., Kairys J, Mastrangelo MJ: Immunopharmacological analysis of an autologous, hapten-modified human melanoma vaccine. J. Clin. Oncol., 22:403-415, 2004 [read more]
Berd D, Sato T, Cohn H, Maguire HC Jr., Mastrangelo, MJ: Treatment of Metastatic Melanoma with Autologous, Hapten-Modified Melanoma Vaccine: Regression of Pulmonary Metastases. Int. J. Cancer 94:531-539, 2001 [read more]
Berd D, Sato T, Mastrangelo MJ: Effect of the Dose and Composition of an Autologous, Hapten-Modified Melanoma Vaccine on the Development of Delayed-Type Hypersensitivity Responses. Cancer Immunol. Immmunother., 51:320-326, 2002
Sensi M., Farina C., Maccalli C., Lupetti R., Nicolini G., Anichini A., Parmiani G., and Berd D: Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine. J. Clin. Invest., 99:710-717, 1997 [read more]
Manne J, Mastrangelo MJ, Sato T, Berd D: T Cell Receptor Rearrangement in Lymphocytes Infiltrating Melanoma Metastases After Administration of Autologous Dinitrophenyl. Modified Vaccine. J. Immunol., 169:3407-3412, 2002 [read more]
Berd D, Murphy G, Maguire HC Jr, Mastrangelo MJ: Immunization With Haptenized, Autologous Tumor Cells Induces Inflammation of Human Melanoma Metastases. Cancer Res, 51:2731-2734, 1991 [read more]
Murphy, G.F., Radu, A., Kaminer, M., and Berd, D.: Autologous melanoma vaccine induces inflammatory responses in melanoma metastases: Relevance to immunologic regression and immunotherapy. J. Invest. Dermatol., 100:335S-341S, 1993 [read more]
Berd D, Maguire HC Jr, and Mastrangelo MJ: Treatment of human melanoma with a hapten-modified autologous vaccine. Ann. N.Y. Acad. Sci., 690: 147-152, 1993
Berd D, Maguire HC Jr, Mastrangelo MJ, and Murphy G: Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine. Cancer Immunol Immunother, 39:141-147, 1994
Sato, T., Maguire, H.C.,Jr., Mastrangelo, M.J., and Berd, D.: Human immune response to DNP-modified autologous cells after treatment with a DNP-conjugated melanoma vaccine. Clin. Immunol.Immunopathol. 74: 35-43, 1995 [read more]
Lattime, E.C., Mastrangelo, M.J., Bagasra, O., Li, W., and Berd, D.: Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol. Immunother., 41:151-156, 1995
Berd D, Maguire HC Jr., Schuchter LM, Hamilton R, Hauck WW, Sato T, Mastrangelo MJ: Autologous, Hapten-Modified Melanoma Vaccine as Post-Surgical Adjuvant Treatment after Resection of Nodal Metastases. J. Clin. Oncol., 15:2359-2370, 1997
Sato, T., Bullock, T.N.J., Eisenlohr, L.C., Mastrangelo, M.J., and Berd, D.: Dinitrophenyl-modified autologous melanoma vaccine induces a T cell response to hapten-modified, melanoma peptides. Clin. Immunol. Immunopathol. 85:265-272, 1997 [read more]
Sensi, M., Farina, C., Maccalli, C., Anichini, A., Berd, D., and Parmiani, G.: Intralesional selection of T-cell clonotype in the immune response to melanoma antigens occurring during vaccination. J. Immunother. 21:198-204, 1998 [read more]
Berd D: Autologous, hapten-modified vaccine as a treatment for human cancer. Vaccine, 19:2565-2570, 2001
Berd D: Contribution of dead cells to the immunogenicity of an autologous, hapten-modified melanoma vaccine. Vaccine, 21:795-797, 2003 [read more]
© 2008 AVAX Technologies, Inc. | Terms